DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced it would report its financial results for the first quarter of 2009 on Wednesday, May 6, 2009 after the close of the financial markets. In addition, Neoprobe announced that two investigators involved in the Company’s Phase 3 clinical trial for Lymphoseek® for patients with breast cancer or melanoma are scheduled to present data related to their experience in the trial on May 7, 2009 at the Third International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy (May 6-9, 2009, San Francisco). The presentation by Dr. Anne Wallace of the Moores Cancer Center at the University of California, San Diego and Dr. Vernon Sondak of the H. Lee Moffitt Cancer Center and Research Institute is titled “Molecular targeting of Sentinel Nodes with Lymphoseek: Phase III Clinical Results for Breast Cancer and Melanoma.” The Company intends to hold a conference call to discuss both the financial results for the first quarter of 2009 and the presentation of the clinical data following the May 7th clinical presentations. The Company has scheduled a conference call with the investment community for the afternoon of Thursday, May 7, 2009 at 4:30 PM ET.
